Eli Lilly and Co CEO Dave Ricks stated that its experimental weight-loss drug orforglipron is expected to be approved as early as early 2026.
Ricks mentioned that the pills would be more convenient for patients and easier to produce on a large scale. The shortage of injections for weight loss under Eli Lilly and Co is partly due to production limitations.
Comment(0)
Reason For Report